08 Mar Cosentyx Delivered Superior Sustained Psoriasis Clearance Compared To Stelara in One Year Study

MedicalResearch.com Interview with:

Dr. Andrew Blauvelt

Dr. Andrew Blauvelt MD MPH
President of Oregon Medical Research Center 

MedicalResearch.com: What is the background for this study?

Dr. Blauvelt: Secukinumab (brand name Cosentyx)is a monoclonal antibody directed against interleukin 17A, a key cytokine involved in psoriasis pathogenesis. Efficacy and safety of secukinumab treatment for moderate-to severe psoriasis has been previously published. There are relatively few head-to-head comparison studies between biologic therapies for psoriasis, making direct comparison of these drugs difficult.

MedicalResearch.com: What are the main findings?

Dr. Blauvelt: CLEAR is 52-week head-to-head study comparing secukinumab (Cosentyx) with ustekinumab (Stelara). 16-week results from the CLEAR study were published last year and showed that secukinumab was significantly superior to ustekinumab in the speed and extent of clearing skin disease in psoriasis patients. At the annual AAD meeting on Saturday March 5 2016, 52-week results were shown for the first time.

Significantly more patients receiving secukinumab for 52 weeks had more clear skin when compared to patients receiving ustekinumab for 52 weeks. Quality of life was also better in secukinumab treated patients when compared to ustekinumab treated patients. No new safety concerns were observed for either drug. This study provides important information for dermatologists who are considering long-term treatment options for their patients with moderate-to-severe psoriasis.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation: 

Blauvelt A et al. Secukinumab demonstrates superior sustained efficacy vs. ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 52-week results from the CLEAR study. Abstract presented at the 74th Annual Meeting of the American Academy of Dermatology. 2016 March 4-8; Washington DC.

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

Dr. Andrew Blauvelt MD MPH (2016). Cosentyx Delivered Superior Sustained Psoriasis Clearance Compared To Stelara in One Year Study MedicalResearch.com

Last Updated on March 8, 2016 by Marie Benz MD FAAD